Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mpox vaccine trial targets HIV-Positive adults in DRC

NCT ID NCT06839989

Ongoing Prevention Sponsor: Institute of Tropical Medicine, Belgium Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether the MVA-BN mpox vaccine is safe and triggers a strong immune response in 600 adults living with HIV in Kinshasa, DRC. Participants receive two vaccine doses 28 days apart and are grouped by their CD4 count. The goal is to see if the vaccine works well for people with different levels of immune health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MVA-BN vaccine (Modified Vaccinia Ankara - Bavarian Nordic)
What this could lead to
If successful, this could show that the MVA-BN vaccine is safe and effective for preventing mpox in people living with HIV, potentially leading to better protection for this vulnerable group.
What could go wrong
This is a mid-stage trial focused on immune response and safety, not on preventing actual mpox infection. Results may not apply to people with very low CD4 counts or outside the DRC.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease monkeypox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MPOX (MONKEYPOX)

Contacts and locations

Locations

  • Centre Hospitalier Kabinda

    Kinshasa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.